

Author: Szalai A.J.
Publisher: Elsevier
ISSN: 0306-3623
Source: General Pharmacology, Vol.39, Iss.3, 2002-08, pp. : 105-107
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


QOL effects of C-reactive protein levels in diabetes
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 442, 2003-01 ,pp. :


Relating statin therapy to C-reactive protein levels
Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. :


C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design, Vol. 13, Iss. 16, 2007-06 ,pp. :

